DocMorris AG

LSE 0RRB.L

DocMorris AG EBITDA for the year ending December 31, 2023: USD -64.81 M

DocMorris AG EBITDA is USD -64.81 M for the year ending December 31, 2023, a 45.41% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

DocMorris AG EBITDA for the year ending December 31, 2022 was USD -118.72 M, a 32.03% change year over year.
DocMorris AG EBITDA for the year ending December 31, 2021 was USD -174.67 M, a -103.12% change year over year.
DocMorris AG EBITDA for the year ending December 31, 2020 was USD -85.99 M, a -509.24% change year over year.
DocMorris AG EBITDA for the year ending December 31, 2019 was USD -14.11 M, a 22.68% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

LSE: 0RRB.L

DocMorris AG

CEO	Mr. Walter Hess
IPO Date	Sept. 12, 2017
Location	Switzerland
Headquarters	WalzmUehlestrasse 60
Employees	1,453
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies E-commerce Retail & Wholesale

Description

DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.

Key trends

Past 5 years